Yes, we should abandon pre-treatment positional testing of the cervical spine.

Musculoskelet Sci Pract

Division of Physiotherapy and Rehabilitation Sciences, University of Nottingham, Nottingham, UK.

Published: October 2020

AI Article Synopsis

  • There is no proven link between cervical spine manipulation and major adverse events (MAE), but manual therapists should still aim to avoid potential risks.
  • Despite recent recommendations, the validity of tests for vertebrobasilar insufficiency (VBI) is low, as they often yield false negatives and aren't reliable indicators of serious neurovascular issues.
  • Patient interviews can effectively identify VBI symptoms and should be prioritized over ineffective VBI tests, which may wrongly suggest that a negative result means it's safe to proceed with manipulation.

Article Abstract

Although there seems to be no causality between cervical spine (CS) manipulation and major adverse events (MAE), it remains important that manual therapists try to prevent every potential MAE. Although the validity of positional testing for vertebrobasilar insufficiency (VBI) has been questioned, recently, the use of these tests was recommended. However, based on the low sensitivity of the VBI tests, which may result in too many false-negative results, the VBI tests seem to be less valuable in pre-manipulative screening. Moreover, because the VBI tests are unable to consistently produce a decreased blood flow in the contralateral vertebral artery in (healthy people), the underlying mechanism of the test may not be a valid construct. There are numerous cases reporting MAE after a negative VBI test, indicating that the VBI tests do not have a role in assessing the risk of serious neurovascular pathology, such as cervical arterial dissection, the most frequently described MAE after CS manipulation. Symptoms of VBI can be identified in the patient interview and should be considered as red flags or warning signs and require further medical investigation. VBI tests are not able to predict MAE and seem not to have any added value to the patient interview with regard to detecting VBI or another vascular pathology. Furthermore, a negative VBI test can be wrongly interpreted as 'safe to manipulate'. Therefore, the use of VBI tests cannot be recommended and should be abandoned.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msksp.2020.102181DOI Listing

Publication Analysis

Top Keywords

vbi tests
24
vbi
11
positional testing
8
cervical spine
8
tests recommended
8
negative vbi
8
vbi test
8
patient interview
8
tests
7
mae
5

Similar Publications

Background: Alcohol dependence remains a significant global health issue, exacerbated by the coronavirus disease 2019 (COVID-19) pandemic. Phosphatidylethanol (PEth), a direct biomarker of recent alcohol consumption, offers improved specificity, sensitivity, and a longer detection window of 2 - 4 weeks compared to traditional biomarkers. This study evaluates the association between PEth testing and hospital outcomes in hospitalized patients by comparing outcomes among patients with positive PEth and negative PEth test results.

View Article and Find Full Text PDF
Article Synopsis
  • People who use drugs (PWUD) face significant risks of hepatitis B (HBV) and delta (HDV) viruses, but awareness of these risks is low among both the affected communities and healthcare providers.
  • The study utilized surveys and interviews in Philadelphia to uncover barriers to HBV and HDV prevention, diagnosis, and care, revealing confusion over insurance and patient hesitancy as key challenges.
  • Findings indicated a widespread lack of knowledge about HBV and HDV, suggesting that educational campaigns should be stigma-free, relatable, and empowering to effectively reach and inform the PWUD community.
View Article and Find Full Text PDF

Adolescents and young adults (AYAs; ages 15-39 years) are a vulnerable population facing challenges in oncological care, including access to specialized care, transition of care, unique tumor biology, and poor representation in clinical trials. Brain tumors are the second most common tumor type in AYA, with malignant brain tumors being the most common cause of cancer-related death. The 2021 WHO Classification for central nervous system (CNS) Tumors highlights the importance of integrated molecular characterization with histologic diagnosis in several tumors relevant to the AYA population.

View Article and Find Full Text PDF

Clinical trial design for novel targeted agents in neuro-oncology.

J Neurooncol

January 2025

Center For Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Article Synopsis
  • Biomarker-based clinical trials for targeted treatments in brain tumors are increasing due to improved testing and understanding of tumor biology.
  • The design of these trials is essential for assessing safety and effectiveness, especially when considering unique challenges faced by brain tumor patients.
  • Trial methodologies like surgical window studies, basket and umbrella trials, and platform trials are helping to evaluate various biomarker-driven approaches while addressing issues of patient diversity and health disparities.
View Article and Find Full Text PDF
Article Synopsis
  • This study evaluates the effectiveness of normalized apparent diffusion coefficient (nADC) versus percentage T2-FLAIR mismatch-volume (%T2FM-volume) in distinguishing IDH-mutant astrocytoma from other glioma types.* -
  • The analysis involved 105 non-enhancing gliomas, utilizing T2-FLAIR digital subtraction maps to identify tumor subregions, yielding results that showed nADC was significantly higher in IDH-mutant astrocytomas compared to other glioma subtypes.* -
  • Overall, nADC was found to be a more reliable classifier than %T2FM-volume, demonstrating higher sensitivity and specificity in identifying IDH-mutant astrocytomas, while survival analysis results indicated a trend
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!